Led by Blatt, Aligos reunites Alios team to develop functional cure for HBV
Led by a team of veterans from Alios BioPharma and Janssen, Aligos Therapeutics raised $125 million in a series B round to bring three of its HBV therapies to the clinic this year. Aligos thinks that in combination, the trio of modalities could lead to the development of a functional HBV cure under one roof.
Wellington Management and an undisclosed global investment management firm led the round. Other new investors include funds managed by Janus Henderson Investor, Boxer Capital